Illumina MiSeq i100 System or equal
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA) has issued a Notice of Intent to Sole Source for the procurement of one (1) Whole Genome Sequencing instrument, specifically an Illumina MiSeq i100 System or equal. This instrument is required for the FDA's Irvine Medical Products Laboratory (IRVLMP) to support the sequencing of microorganisms from regulatory pharmaceutical samples. Interested parties must submit capability statements by March 26, 2026, at 2:30 PM ET.
Scope of Work
The requirement is for a single Whole Genome Sequencing instrument for the IRVLMP in Irvine, CA. The instrument must be an Illumina MiSeq i100 System or an equivalent product that meets all identified salient characteristics. Key technical requirements include:
- Uses sequencing-by-synthesis next-generation sequencing technology.
- Supports single-read and paired-end libraries.
- Output range up to 25 Gigabases.
- Up to 200 million paired-end reads per run.
- Maximum read length of at least 2 x 500 base pairs.
- ≥85% of bases achieving Q30 at 2 x 300bp.
- RFID or equivalent consumable tracking.
- Reagents stored at room temperature.
- Includes onboard data collection and sequence alignment software.
- Includes monitor and control computer.
- Benchtop system not exceeding 16" x 18" x 26" (W×D×H).
Contract & Timeline
- Notice Type: Special Notice (Notice of Intent to Sole Source)
- Anticipated Award Type: Firm-Fixed-Price purchase order
- Set-Aside: None specified
- Warranty: Minimum one (1) year manufacturer's warranty covering parts and labor, beginning upon Government acceptance.
- Delivery: Within 60 days after award to FDA / IRVLMP, 19701 Fairchild, Irvine, CA 92612.
- Response Due: March 26, 2026, at 2:30 PM ET
- Published: March 20, 2026
Response Instructions
Interested parties capable of meeting the requirements must submit capability statements. Offerors proposing an equivalent product must clearly demonstrate how their proposed product meets each of the salient characteristics outlined in the Statement of Work.
Contact Information
- Contracting Officer: Iris Johnson
- Email: Iris.Johnson1@fda.hhs.gov